MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
February 10, 2022 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
January 24, 2022 06:00 ET
|
MediWound Ltd.
Primary Endpoint Met with Highly Statistically Significant ResultsNo Observed Safety IssuesFinal Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, Jan. 24, 2022 (GLOBE NEWSWIRE) --...
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
December 20, 2021 07:00 ET
|
MediWound Ltd.
Data Demonstrate EscharEx Reduces Biofilm and Bacterial BurdenEscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:...
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
December 06, 2021 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
November 18, 2021 07:30 ET
|
MediWound Ltd.
YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
MediWound Reports Third Quarter 2021 Financial Results
November 16, 2021 07:00 ET
|
MediWound Ltd.
Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21% Clarity on Regulatory Pathway for Resubmission of NexoBrid BLA, Anticipated in Mid- 2022 EscharEx Phase 2...
MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021
November 04, 2021 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
October 04, 2021 07:30 ET
|
MediWound Ltd.
YAVNE, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
MediWound to Present at Upcoming Investor Conferences
September 03, 2021 16:14 ET
|
MediWound Ltd.
YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
MediWound Reports Second Quarter Financial Results
August 10, 2021 07:00 ET
|
MediWound Ltd.
Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety...